RNF168 and cancer: For example, reducing the expression of Sentrin/SUMO specific protease 1 (SENP1) can improve DDR efficiency and cancer cells’ resistance to DNA damaging agents, which is related to SENP1 preventing RNF168 from forming nuclear condensate and confirming that SENP1 is a potential target for cancer therapy (110).